Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1975 1
1976 1
1985 2
1986 2
1987 1
1988 5
1989 5
1990 2
1991 5
1992 3
1993 4
1994 4
1995 6
1996 4
1997 10
1998 5
1999 5
2000 3
2001 7
2002 6
2003 4
2004 3
2005 7
2006 4
2007 4
2008 5
2009 1
2010 3
2011 5
2012 9
2013 9
2014 10
2015 13
2016 4
2017 12
2018 7
2019 4
2020 5
2021 3
2022 3
2023 8
2024 7
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.
Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, Kerr-Conte J, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Blanck S, Vandel J, Olsson L, Chakaroun R, Gnemmi V, Leteurtre E, Lefebvre P, Haas JT, Yki-Järvinen H, Francque S, Staels B, Le Roux CW, Tremaroli V, Mathurin P, Marot G, Romeo S, Pattou F. Raverdy V, et al. Among authors: lefebvre p. Nat Med. 2024 Dec;30(12):3624-3633. doi: 10.1038/s41591-024-03283-1. Epub 2024 Dec 9. Nat Med. 2024. PMID: 39653777 Free PMC article.
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
Pawlak M, Lefebvre P, Staels B. Pawlak M, et al. Among authors: lefebvre p. J Hepatol. 2015 Mar;62(3):720-33. doi: 10.1016/j.jhep.2014.10.039. Epub 2014 Nov 1. J Hepatol. 2015. PMID: 25450203 Free article. Review.
Peroxisome proliferator-activated receptor alpha (PPARalpha) is a ligand-activated transcription factor belonging, together with PPARgamma and PPARbeta/delta, to the NR1C nuclear receptor subfamily. ...
Peroxisome proliferator-activated receptor alpha (PPARalpha) is a ligand-activated transcription factor belonging, together with PPAR …
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Chávez-Talavera O, et al. Among authors: lefebvre p. Gastroenterology. 2017 May;152(7):1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055. Epub 2017 Feb 15. Gastroenterology. 2017. PMID: 28214524 Free article. Review.
Bile acids are signaling molecules that coordinately regulate metabolism and inflammation via the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5). These receptors activate transcriptional networks and signaling cascades c …
Bile acids are signaling molecules that coordinately regulate metabolism and inflammation via the nuclear farnesoid X receptor (FXR) …
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.
Gross B, Pawlak M, Lefebvre P, Staels B. Gross B, et al. Among authors: lefebvre p. Nat Rev Endocrinol. 2017 Jan;13(1):36-49. doi: 10.1038/nrendo.2016.135. Epub 2016 Sep 16. Nat Rev Endocrinol. 2017. PMID: 27636730 Review.
The peroxisome proliferator-activated receptors (PPARs) modulate several biological processes that are perturbed in obesity, including inflammation, lipid and glucose metabolism and overall energy homeostasis. ...
The peroxisome proliferator-activated receptors (PPARs) modulate several biological processes that are perturbed in obesity, includin …
Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Lefebvre P, et al. Physiol Rev. 2009 Jan;89(1):147-91. doi: 10.1152/physrev.00010.2008. Physiol Rev. 2009. PMID: 19126757 Free article. Review.
The metabolic syndrome can be defined as a cluster of cardiovascular disease risk factors including visceral obesity, insulin resistance, dyslipidemia, increased blood pressure, and hypercoagulability. The farnesoid X receptor (FXR) belongs to the superfamily of ligand-act …
The metabolic syndrome can be defined as a cluster of cardiovascular disease risk factors including visceral obesity, insulin resistance, dy …
PPARs in liver physiology.
Berthier A, Johanns M, Zummo FP, Lefebvre P, Staels B. Berthier A, et al. Among authors: lefebvre p. Biochim Biophys Acta Mol Basis Dis. 2021 May 1;1867(5):166097. doi: 10.1016/j.bbadis.2021.166097. Epub 2021 Jan 29. Biochim Biophys Acta Mol Basis Dis. 2021. PMID: 33524529 Free article. Review.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and transcriptional modulators with crucial functions in hepatic and whole-body energy homeostasis. ...
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and transcriptional modulators with crucial function …
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Dormandy JA, et al. Among authors: lefebvre pj. Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9. Lancet. 2005. PMID: 16214598 Free article. Clinical Trial.
There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients …
There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular …
Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr-deficient mice.
Henry D, Baugé E, Hennuyer N, Ory K, Derudas B, Vallez E, Deprince A, Lefebvre P, Haas JT, Staels B, Lalloyer F. Henry D, et al. Among authors: lefebvre p. Sci Transl Med. 2025 May 28;17(800):eadj8192. doi: 10.1126/scitranslmed.adj8192. Epub 2025 May 28. Sci Transl Med. 2025. PMID: 40435217
Atherogenic dyslipidemia and chronic inflammation appear strongly associated with residual cardiovascular disease (CVD) risk. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists, which exert both triglyceride-lowering and anti-inflammatory properties, are …
Atherogenic dyslipidemia and chronic inflammation appear strongly associated with residual cardiovascular disease (CVD) risk. Peroxisome pro …
Nur77turing macrophages in atherosclerosis.
Lefebvre P, Chinetti G, Staels B. Lefebvre P, et al. Circ Res. 2012 Feb 3;110(3):375-7. doi: 10.1161/CIRCRESAHA.111.263178. Circ Res. 2012. PMID: 22302751 Free article. No abstract available.
Auditory function and dysfunction: estrogen makes a difference.
Delhez A, Lefebvre P, Péqueux C, Malgrange B, Delacroix L. Delhez A, et al. Among authors: lefebvre p. Cell Mol Life Sci. 2020 Feb;77(4):619-635. doi: 10.1007/s00018-019-03295-y. Epub 2019 Sep 14. Cell Mol Life Sci. 2020. PMID: 31522250 Free PMC article. Review.
197 results